Moreover, RRM2 promoted RCC cell acquired resistance to VEGF tyrosine kinase inhibitors, inhibiting the effect of PD-1 blocker immunotherapy (Xiong et al., 2021). Here, RRM2 is linked to renal cell carcinoma.